CoChat

What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials

Open access
Bullain, Szofia, Doody, Rachelle · 2020 · Journal of Neurochemistry
Cited by 38

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder with no approved disease‐modifying therapy (DMT). In this review, we summarize the various past approaches taken in an attempt to find treatments capable of altering the long‐term course for individuals with AD, including: translating epidemiological observations into potential treatment options; seeking a single‐treatment approach across the continuum of AD severity; utilizing biomarkers for assessing target engagement; using biomarkers as early surrogates of clinical efficacy; and enriching study populations to demonstrate adequate placebo decline during the limited duration of clinical trials. Although targeting the amyloid‐β (Aβ) pathway has been central to the search for an effective DMT, to date, trials of anti‐Aβ monoclonal antibodies have failed to consistently demonstrate significant clinical efficacy. Key learnings from these anti‐Aβ trials, as well as the trials that came before them, have shifted the focus within clinical development programs to identifying target populations thought most likely to benefit from treatments (i.e., individuals at an earlier stage of disease). Other learnings include strategies to increase the likelihood of showing measurable improvements within the clinical trial setting by better predicting decline in placebo participants, as well as developing measures to quantify the needed treatment exposure (e.g., higher doses). Given the complexity associated with AD pathology and progression, treatments targeting non‐amyloid AD pathologies in combination with anti‐amyloid therapies may offer an alternative for the successful development of DMTs. image

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jnc.15023

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 38

Metadata

Authors
Bullain, S., & Doody, R.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2020-05-09
Volume
155
Issue
2
Pages
120-136
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W3015590050
Cited by
38
References
38
FWCI
4.15
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials. https://app.cochat.ai/papers/10.1111/jnc.15023
The paper
Bullain, S., & Doody, R. (2020). What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials. Journal of Neurochemistry. https://doi.org/10.1111/jnc.15023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.